Jason Rifkin is interim-Chief Executive Officer. Jason has been an executive in early stage biotechnology, pharmaceutical and medical device companies in numerous indications, and has managed all aspects of operations including clinical and scientific affairs, business development, licensing, and intellectual property pursuits. For the past ten years, he has focused on tactical execution of early stage business plans to build companies and technologies through pre-commercial inflection points, and hit important early development milestones. In addition to Jason’s role as interim-CEO of Cage Pharma, he is President and CEO of AAVP Biosystems, Inc., a targeted gene therapy company, and previously held roles of Vice President of Business and Contract Development of AZTherapies, Inc., a late-stage clinical development company enrolling a Phase 3 Alzheimer’s study; Director of Business Development at MAX BioPharma, Inc., an early stage osteoporosis company; Executive Vice President of PalliaTech, Inc., a palliative care company focused on the development of palliative care focused therapeutics; and Senior Vice President of Delcath Systems, Inc. a publically traded oncology focused company. Jason earned a Master’s of Science in Biotechnology from The University of Pennsylvania, School of Engineering and Applied Science, a Juris Doctor from Northeastern University School of Law, and a Bachelor of Science from The University of Pennsylvania, College of Arts and Sciences.